CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics

Volume: 19, Issue: 1
Published: Jan 8, 2019
Abstract
Genome editing allows for the precise manipulation of DNA sequences in a cell making this technology essential for understanding gene function. CRISPR/Cas9 is a targeted genome-editing platform derived from bacterial adaptive immune system and has been repurposed into a genome-editing tool. The RNA-guided DNA endonuclease, Cas9 can be easily programmed to target new sites by altering its guide RNA sequence, making this technology easier, more...
Paper Details
Title
CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics
Published Date
Jan 8, 2019
Volume
19
Issue
1
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.